Selection of adjuvant chemotherapy for treatment of node-positive breast cancer (Q36300761)

13 August 2017

1 reference

title

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer (English)

1 reference

13 August 2017

1 reference

1 reference

9

Louise Provencher

0 references

author name string

Maureen Trudeau

1

1 reference

13 August 2017

Flay Charbonneau

2

1 reference

13 August 2017

Karen Gelmon

3

1 reference

13 August 2017

Kara Laing

4

1 reference

13 August 2017

Jean Latreille

5

1 reference

13 August 2017

John Mackey

6

1 reference

13 August 2017

Deanna McLeod

7

1 reference

13 August 2017

Kathy Pritchard

8

1 reference

13 August 2017

Shailendra Verma

10

1 reference

13 August 2017

1 November 2005

1 reference

Lancet Oncology Commission

13 August 2017

1 reference

13 August 2017

6

1 reference

13 August 2017

11

1 reference

13 August 2017

886-898

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast canc

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970424-1

7 January 2021

10.1016/S1470-2045(05)70424-1

Identifiers

DOI

1 reference

13 August 2017

1 reference